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The TNF family cytokines B-cell activating factor (BAFF) and a proliferation-inducing lig-
and (APRIL) support plasma cell survival. It is known that inhibitors of BAFF only (BAFFR-
Fc) or BAFF and APRIL (TACI-Fc) administered early enough in an NZB/NZW F1 mouse
model of systemic lupus erythematosus (SLE) ameliorate clinical outcomes, pointing to a
pathogenic role of BAFF. In the present study, TACI-Fc administrated at a later stage of
disease, after onset of autoimmunity, decreased the number of bonemarrow plasma cells
and slowed down further formation of autoantibodies. TACI-Fc prevented renal damage
during a 12-week treatment period regardless of autoantibody levels, while BAFFR-Fc
did not despite a similar BAFF-blocking activity in vivo. TACI-Fc also decreased estab-
lished plasma cells in a T-dependent hapten/carrier immunization system better than
single inhibitors of BAFF or APRIL, and sometimes better than combined single inhibitors
with at least equivalent BAFF and APRIL inhibitory activities. These results indicate that
TACI-Fc can prevent symptoms of renal damage in a mouse model of SLE when BAFFR-Fc
cannot, and point to a plasticity of plasma cells for survival factors. Targeting plasma cells
with TACI-Fc might be beneficial to prevent autoantibody-mediated damages in SLE.
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Introduction
The homotrimeric TNF family ligands BAFF (B cell-activating fac-
tor of the TNF family, also known as B Lymphocyte stimula-
tor) [1, 2] and APRIL (A proliferation-inducing ligand) [3] are
important differentiation and survival cytokines for B cells. BAFF
and APRIL can also form heterotrimers whose biological relevance
remains unknown [4–6]. BAFF engages three specific receptors,
BCMA (B cell maturation antigen) [7, 8], TACI (transmembrane
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activator and CAML interactor) [9] and BAFFR (BAFF recep-
tor) [10], while APRIL binds to BCMA, TACI and, via another
portion of its structure, to sulfated glycosidic chains of proteo-
glycans [11, 12]. BAFF-deficient mice have reduced numbers of
peripheral B cells, showing that BAFF is required for mature B cell
survival in vivo [13, 14]. The phenotype of APRIL-deficient mice
is milder, with impaired class switch recombination to IgA [15]. It
is BAFFR that mediates BAFF survival signals in transitional and
mature B cells [10, 16]. TACI is required for T-independent anti-
body responses and to negatively regulate the B-cell pool [17, 18].
∗These authors share senior authorship.
C© 2017 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
www.eji-journal.eu
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial
4.0 License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited and is not used for commercial purposes.
1076 P. Haselmayer et al. Eur. J. Immunol. 2017. 47: 1075–1085
BCMA contributes to the maintenance of terminally differentiated
plasma cells (PCs) [19]. APRIL, together with IL-6 and stromal
cell-derived factors can be used to generate and indefinitely sup-
port human long-lived PC in vitro [20].
In the population of patients suffering from certain autoim-
mune diseases, elevated levels of soluble BAFF and/or APRIL can
be detected [21–23]. Mice genetically modified to over-express
BAFF develop symptoms of a systemic lupus erythematosus (SLE)-
like autoimmunity [7, 24]. Excess BAFF may favor autoimmunity
via partial subversion of B-cell self-tolerance at the level of na¨ıve
B cells [25]. At the level of antigen-experienced mature B cells,
a model of competitive elimination for chronically stimulated B
cells, which require BAFF for survival, has been proposed [26].
BAFF antagonism has proven efficacious in a number of different
animal models for human SLE [27–31], while selective neutral-
ization of APRIL in a mouse model of SLE only modestly delayed
disease apparition [32]. In a particular congenic inbred mouse
strain, which serves as a model for human SLE, BAFF, APRIL, and
their receptors have been genetically deleted [33–37]. Deletion of
APRIL, BAFFR, BCMA, or TACI did not ameliorate SLE. Deletion
of BAFF delayed apparition of autoantibodies and deposition of
immune complexes, and attenuated disease severity [35], as did
deletion of BAFFR plus either BCMA or TACI [37]. Deletion of
both BAFF and APRIL decreased the bone marrow PC compart-
ment and strongly reduced IgG anti-chromatin and anti-dsDNA
antibody levels, an effect not observed by deletion of BAFF or
APRIL separately [34, 35]. These data show that maximal sup-
pression of autoimmunity is achieved by dual BAFF and APRIL
inhibition, even though this did not further improved health of
mice compared to BAFF deletion alone in the experimental win-
dow examined and raised the concern of side effects caused by
excessive depression of the humoral response.
In the present study, we compared pharmacological inhibition
of BAFF (using mouse BAFFR-Fc, mBAFFR-Fc), or of BAFF and
APRIL (using mouse TACI-Fc, mTACI-Fc) in SLE-prone mice
with declared autoimmunity and found that TACI-Fc, but not
BAFFR-Fc, prevented renal pathology even in the presence
of autoantibodies. We also report that in immunized, non-
autoimmune mice, 2 weeks’ treatment with TACI-Fc, but not with
BAFFR-Fc, decreased both recently-generated and long-lived PCs
in the bone marrow, but that the latter were not depleted by
the combined action of single BAFF and APRIL inhibitors. We
conclude that, at least under specific circumstances, TACI-Fc does
more than single BAFF inhibition to reduce PCs and to decrease
SLE symptoms. Our results also suggest that PC responses to
survival factors can change as they age.
Results
In vitro characterization of a function-blocking
anti-mouse APRIL antibody
Because BCMA participates to survival and longevity of PCs in the
bone marrow [19] and displays a higher affinity for APRIL than
for BAFF [38], APRIL is likely to transmit survival signal to PCs.
We characterized an antibody suitable for pharmacological inhi-
bition of mouse APRIL. This reagent, Apry-1-1, is a human single
chain monoclonal antibody dimerized by fusion to the Fc portion
of mouse IgG2b. Apry-1-1 specifically recognized and inhibited
mouse APRIL in a variety of settings in vitro and compared favor-
ably with hTACI-Fc in terms of mouse APRIL inhibition (Support-
ing Information Fig. 1).
TACI-Fc, but not BAFFR-Fc, arrests disease
progression in NZB/NZW F1 mice
The NZB/NZW F1 mouse model of SLE was used to compare
pharmacological inhibitors and assess the contributions of BAFF
and APRIL to disease progression. In the absence of treatment,
NZB/NZW F1 mice started to produce anti-dsDNA IgGs at 20- to
22-week-old, and most of themwere positive at week 24 (Fig. 1A).
At that stage, mice were still negative for proteinuria (Fig. 1B) and
corresponded in terms of clinical manifestations to patients with
low disease activity. Mice were separated in groups with compa-
rable autoantibody distributions and were treated from week 25
to week 37 with inhibitors of BAFF and/or APRIL. The different
control groups were pooled for the analysis because we noticed no
difference between them. Mice treated with mTACI-Fc remained
negative for proteinuria at all time points, in contrast to controls
in which the percentage of affected mice steadily increased up to
week 37 (Fig. 1B). Mice treated with Apry-1-1 were as affected
as controls, and mice receiving mBAFFR-Fc only showed a non-
significant trend to delayed onset of proteinuria (Fig. 1B). In all
unprotected groups including the one treated with mBAFFR-Fc,
once proteinuria became positive, UPCR increased to high values
over just 1–2 weeks (Fig. 1C).
TACI-Fc and BAFFR-Fc inhibit BAFF similarly, but
Apry-1-1 is inactivated in NZB/NZW F1 mice
Anti-BAFF activity in vivo can be visualized by depletion of mature
splenic B cells within 2 weeks [39]. In mice treated with mTACI-Fc
or mBAFFR-Fc, splenic B cells were depleted (Fig. 1D, Supporting
Information Fig. 2). Anti-BAFF and anti-APRIL inhibitory activi-
ties were also measured directly in sera at three different time
points of treatment using a cell-based assay. Briefly, BCMA:Fas
reporter cells exposed to recombinant BAFF or APRIL die by acti-
vation of the surrogate Fas apoptotic pathway. Active inhibitors
in sera are monitored for their capacity to protect reporter cells
from BAFF- or APRIL-mediated death. Anti-mBAFF activities were
comparable in mTACI-Fc- and mBAFFR-Fc-treated mice, slightly
higher in the mTACI-Fc group, but in any case present in excess
(Fig. 1E). mTACI-Fc had a low but significant mAPRIL inhibitory
action. Unexpectedly, Apry-1-1 treatment generated no anti-APRIL
activity in sera of most treated mice (Fig. 1F), even though Apry-
1-1 was superior to mTACI-Fc in vitro (Supporting Information
Fig. 1H). Instead, sera of Apry-1-1-treated animals could inhibit
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exogenously added Apry-1-1 up to high levels in the reporter cell
assay (Fig 1G). This strongly suggests that autoimmune NZB/NZW
F1micemounted a rapid and efficient anti-drug antibody response
against Apry-1-1, thus invalidating this arm of the study. Results
obtained with Apry-1-1 treatment are therefore shown with the
indication of Apry-1-1 in double brackets to indicate that the
active agent had been neutralized. In contrast, excess neutraliz-
ing activity against mTACI-Fc or mBAFFR-Fc was not detected, as
demonstrated by the positive anti-BAFF activity present in these
samples (Fig. 1E).
TACI-Fc diminishes bone marrow PC numbers and
stabilizes autoantibody secretion in NZB/NZW F1 mice
In order to document specific changes induced in mTACI-Fc-
treated mice, we enumerated antibody-secreting cells and mea-
sured CD138+ PCs in the spleen and bone marrow. In the spleen,
mTACI-Fc, and to a lesser extent mBAFFR-Fc, reduced antibody-
secreting cell numbers and showed a trend toward reduction of
CD138+ cells (Fig. 2A and B). In the bone marrow, mBAFFR-Fc
and mTACI-Fc decreased antibody-secreting cell numbers, with
the effect being more pronounced for mTACI-Fc (Fig. 2C). Only
mTACI-Fc significantly reduced CD138+ cells in the bone mar-
row (Fig. 2D). In the control group, autoantibodies increased or
remained high in most animals, while they were stabilized at
roughly initial levels in mTACI-Fc-treated mice (Fig. 2E). When
only considering mice with relatively low autoantibody levels at
week 24, i.e. those mice into which large increase of autoantibod-
ies was possible, mTACI-Fc prevented evolution to high autoanti-
body levels (Fig. 2F).
TACI-Fc decreases renal histopathology even in the
presence of autoantibodies
Upon termination of the study at the age of 37 weeks, kidneys
from control mice showed pronounced multifocal to generalized
glomerular damage, obliteration of Bowman space, glomerular
compression and glomerular sclerosis (Fig. 3A, left panel). In
contrast, kidneys from mTACI-Fc-treated mice were protected
(Fig. 3B) with significantly lower renal histopathology scores (Fig.
2G), while those of mBAFFR-Fc-treated mice were intermediate
between the control and mTACI-Fc groups (Fig. 3C and 2G). We
next investigated the relationship between autoantibody levels
and renal pathology. In the control group, with a few exceptions,
high levels of anti-dsDNA IgG at weeks 24–28 were associated
with high proteinuria scores and vice-versa (Fig. 2H). This cor-
relation was absent in mTACI-Fc-treated mice, where proteinuria
did not develop even in mice with high anti-dsDNA titers. A pos-
sible intermediate situation was observed in mBAFFR-Fc treated
mice (Fig. 2H).
Taken together, these results indicate that treatment with
mTACI-Fc reduces PC numbers in the bone marrow and slows
down autoantibody production, with effects probably extend-
ing beyond the mere control of PCs and anti-dsDNA IgGs,
as mice with high and low autoantibody levels were equally
protected.
TACI-Fc-induced decrease of PC is not recapitulated
with a combination of BAFF and APRIL inhibitors
How inhibitors impact bone marrow PC survival was addressed
in C57BL/6 mice immunized with NP-conjugated keyhole limpet
hemocyanin. Following immunization, mice were rested for 2, 5
or 12 weeks before initiation of a 2-week treatment, after which
time activities of inhibitors were monitored in sera, and levels
of splenic B cells and NP-specific bone marrow PCs were deter-
mined. Anti-BAFF activities in sera were comparable at all time
points for mTACI-Fc, mBAFFR-Fc given alone and mBAFFR-Fc
given together with Apry-1-1 (Fig. 4A). Anti-APRIL activity of
mTACI-Fc was detectable but surprisingly low, as already observed
in the SLE model, while activity of Apry-1-1 alone or together with
mBAFFR-Fc was present and higher than that observed for mTACI-
Fc (Fig. 4B). Thus, unlike what was observed in the SLE model,
Apry-1-1 remained active in immunized C57BL/6 mice. Finally,
serum anti-BAFF and anti-APRIL activities of hTACI-Fc were one
to two orders of magnitude higher than those of other inhibitors
tested (Fig. 4A and B). As anticipated, mTACI-Fc, hTACI-Fc and
mBAFFR-Fc all decreased BAFF-dependent splenic B cells, while
Apry-1-1 did not (Fig. 4C). For bone marrow PCs, the effect of
BAFF and/or APRIL inhibition was dependent on the timing of
inhibitor administration post-immunization. PCs at 2 weeks were
decreased upon treatment with mTACI-Fc, hTACI-Fc or combined
mBAFFR-Fc/Apry-1-1, but not with mBAFFR-Fc alone, and only
to a lesser extent with Apry-1-1 alone (Fig 4D, top panel). This
suggests that early PCs can survive in response to either BAFF
or APRIL, and that both APRIL and BAFF are present in suffi-
cient amounts to support this population. At 5 weeks, mTACI-
Fc and hTACI-Fc efficiently depleted PCs. Apry-1-1, alone or in
combination with mBAFFR-Fc, also significantly reduced PCs, but
to a lower extent than TACI-Fc, while mBAFFR-Fc showed no
efficacy (Fig. 4D, middle panel). This suggests that at week 5, PCs
might rely more strongly on APRIL than on BAFF. At week 12,
when long-lived PCs were measured, the variability of the assay
was relatively high, and only mTACI-Fc treatment significantly
decreased PCs. PCs were also low in all hTACI-Fc-treated animals
(but statistically non-significant because of the relatively low num-
ber of mice in this group) (Fig 4D, bottom panel). Single BAFF or
APRIL inhibitors, alone or in combination, did not decrease PCs at
that stage. Especially, in the mBAFFR-Fc/Apry-1-1 group, despite
homogenous anti-BAFF and anti-APRIL activities (Fig. 4A and B),
numbers of PCs were very heterogeneous with a mean not differ-
ent from that of the control group (Fig. 4D, bottom panel). We
conclude that long-lived PCs are decreased by TACI-Fc, but not by
separate inhibitions of BAFF and APRIL.
Taken together, these observations confirm that TACI-Fc, but
not BAFFR-Fc, can inhibit bone marrow PC, including long-lived
ones [40]. They further indicate that combined inhibition of BAFF
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and APRILwith two specific inhibitors does not always recapitulate
the action of TACI-Fc on long-lived PCs, and suggest that PCs at
different stages of maturation may rely on different combinations
of survival cytokines.
Discussion
This study was designed to compare single versus dual pharma-
cological inhibitions of BAFF and APRIL in a mouse model of
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1075–1085 Immunomodulation and immune therapies 1079
SLE and in a hapten/carrier immunization model. We used an
anti-mAPRIL single-chain monoclonal antibody for specific APRIL
inhibition, mBAFFR-Fc for single BAFF inhibition and mTACI-Fc,
the mouse equivalent of atacicept currently being developed as a
treatment for SLE [41], for dual BAFF and APRIL inhibition.
Quantification of inhibitor activity in sera of experimental ani-
mals was informative. First, most autoimmunity-prone NZB/NZW
F1 mice mounted a robust neutralizing antibody response to the
anti-APRIL antibody Apry-1-1 but this anti-drug response was not
detected after 2 weeks of treatment in C57BL/6 mice in the hap-
ten/carrier immunizationmodel. Second, the BAFF-blocking activ-
ity of mBAFFR-Fc was comparable to that of mTACI-Fc in vitro
and in vivo in both animal models used. Third, in terms of APRIL-
neutralizing activity, hTACI-Fc and Apry-1-1 behaved identically
in vitro, but the later displayed a 30- to 300-fold lower activity
in vivo in C57BL/6 mice, in the absence of a detectable anti-
drug response. Fourth, hTACI-Fc inhibited mBAFF and mAPRIL
in vitro and in vivo. In comparison, after normalization to anti-
mBAFF activity, mTACI-Fc was five-fold less active against mAPRIL
in in vitro assays. The molecular basis for this intrinsic par-
tial deficit of mTACI-Fc toward mAPRIL inhibition is unknown.
The anti-mAPRIL activity of mTACI-Fc in vivo dropped even
further, possibly because a fraction of this close-to-limiting activ-
ity became occupied by endogenous ligands. All in all, mBAFFR-Fc
and mTACI-Fc inhibited mBAFF similarly in all experiments, while
Apry-1-1 could inhibit more mAPRIL than mTACI-Fc in C56BL/6
mice but was inactivated in autoimmune mice. The latter result
might be explained by the presence of human sequences in Apry-
1-1.
Previous studies conducted in NZB/NZW F1 and related mouse
models of lupus have led to the general conclusion that TACI-Fc
and BAFFR-Fc were equally efficient to prevent lupus when admin-
istered as single agents before development of proteinuria, or to
arrest or even reverse further disease development when admin-
istered together with CTLA4-Fc, a T-cell inhibitor, after onset of
proteinuria [13, 28–30]. This, together with the modest effect
of anti-APRIL therapy observed in this model [32], indicated a
predominant pathological role of BAFF in mouse SLE, with no or
little contribution of APRIL. In agreement with others, we found
that TACI-Fc as single agent strongly impaired disease progres-
sion, even though we initiated treatment at a later time point,
when autoantibodies were already present and proteinuria about
to appear. However, we observed that BAFFR-Fc was far less effi-
cient than TACI-Fc in arresting SLE, which, at first sight, contrasts
with previous publications. It is, however, noteworthy that even
in our study, mBAFFR-Fc had signs of efficacy when renal pathol-
ogy was assessed (Fig. 2G). Discrepancies observed for the effi-
cacy of BAFFR-Fc might reflect different experimental conditions.
Housing conditions or other variables could differently modulate
kinetics and penetrance of disease. Also, timing of treatment was
different in our study compared to the most similar one performed
in NZB/NZW F1, where treatment was initiated in a prophylactic
manner at weeks 18–20, before declared autoimmunity (see Fig.
1A) [30, 31]. In this prophylactic study, appearance of proteinuria
in mBAFFR-Fc-treated mice was delayed by 24 weeks (50% pro-
teinuria 300 mg/dL at week 55 instead of week 31 in controls)
and death was remarkably delayed (50% survival at week 35 in
untreated, versus week 65 in treated) [30]. Other differences were
the dose and mode of inhibitor administration: mBAFFR-Fc was
expressed from a single administration of adenovirus, resulting
in very high expression during the first 2 weeks reaching up to
500 μg/mL in serum before declining to about 20 μg/mL after 5
weeks; it cannot be fully excluded that mBAFFR-Fc at high concen-
trations might have cross-reacted to partially or entirely neutralize

Figure 1. mTACI-Fc, not mBAFFR-Fc, prevents proteinuria in NZB/NZW F1 mice with declared autoimmunity, while anti-APRIL Apry-1-1 is
neutralized by an anti-drug antibody response. (A). Longitudinal assessment of anti-dsDNA antibody levels in NZB/NZW F1 mice. Sera were
prepared from cohorts of NZB/NZW F1 mice at the indicated ages. Relative titers of anti-dsDNA IgG were determined by ELISA in triplicate
titrations. Pooled data from controls of 4 experiments. Number of sera analyzed at weeks 12/16/20/22/24/30/34/38 were 70/65/25/70/60/55/49/31.
(B). NZB/NZW F1 mice were treated for 12 weeks, three times a week, with mTACI-Fc, mBAFFR-Fc, anti-mAPRIL Apry-1-1 or appropriate controls
starting at 25 weeks of age (n = 15 for mTACI-Fc and mBAFFR-Fc, n = 14 for Apry-1-1, n = 44 for pooled mFc, mIgG and untreated controls), when
the majority of mice were positive for anti-dsDNA and negative for proteinuria. Kaplan-Meier plot depicting the fraction of mice over time that
developed proteinuria (defined as UPCR  3). (C). Kinetics of urinary protein to creatinine ratio (UPCR) increase, where week 1 is defined as the
first week when a given mouse had a UPCR 3. Only the subset of mice shown in panel 1B that developed proteinuria is analyzed (at week 1, n
= 28 for controls, n = 7 for BAFFR-Fc, n = 6 for Apry-1-1). Mice treated with mTACI-Fc do not appear on this graph because they did not develop
proteinuria. UPCR was measured once per mouse and time point. (D). Absolute B cell numbers (CD19+ and B220+) found in the spleen of NZB/NZW
F1 mice as determined by FACS analysis on the day of sacrifice at 12 weeks of treatment (n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1: 26/15/11/4) or
before 12 weeks of treatment (n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1: 18/0/4/9). (E). Amounts of mBAFF-neutralizing activities were measured
at weeks 3, 7 and 12 of the indicated treatments using a cell-based reporter assay (BCMA:Fas reporter cells). Each point represents the EC50 of
a titration of recombinant Fc-mBAFF performed on BCMA:Fas reporter cells in the presence of serum diluted 1/300. Number of sera analyzed for
controls/TACI-Fc/BAFFR-Fc/Apry-1-1 at weeks 3, 7 and 12 were 45/15/15/15, 40/15/15/13 and 25/15/14/7, respectively. Sera of mice sacrificed before
3, 7, and 12 weeks of treatment were respectively assigned to groups 3, 7, and 12 weeks. Each value was obtained from the EC50 of a titration
performed once. (F). Same as panel E, but for the measure of Fc-mAPRIL-neutralizing activity. (G). Quantification of anti-drug antibody (ADA)
response directed against Apry-1-1 in sera of mice treated for 3, 7, or 12 weeks with Apry-1-1 or in untreated controls. For that purpose, BCMA:Fas
reporter cells were exposed to a fixed lethal concentration of Fc-mAPRIL, but rescued in the presence of titrated concentrations of pure Apry-1-1.
The anti-Apry-1-1 ADA response was measured as the capacity of sera diluted 1/300 to prevent rescue of reporter cells by pure Apry-1-1. Number
of sera analyzed for untreated controls/Apry-1-1 at weeks 3, 7 and 12 were 15/15, 13/13, and 4/7, respectively. Each value was obtained from the
EC50 of a titration performed once. Panels A and D-G show mean of each group ± SEM, with symbols representing individual mice. Panel C shows
mean ± SD. The experiment analyzed in panels 1B - 1G was performed once. Analyses were performed once, except those of panels E-G that were
performed twice with similar results in two independent sets of measurements of the same set of sera. Statistical analysis was performed with
Mantel-Cox test (B), one-way ANOVA followed by Bonferroni comparing controls to each treatment (D-F), and unpaired t-test comparing untreated
to treated (G). ns: nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2. mTACI-Fc is more effective thanmBAFFR-Fc in diminishing the bone marrow PC compartment and in preventing autoantibody increase
and renal immunopathology in NZB/NZW F1 mice. (A). Antibody secreting cells (ASC) retrieved from spleens of 37-week-old NZB/NZW F1 mice
subjected to the indicated treatments, as determined by ELISPOT. n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1 were 25/15/11/4. Values were obtained
from titrations performed in triplicates. (B). Numbers of PCs (CD138+) derived from spleens of NZB/NZW F1 mice. Absolute cell numbers were
determined by FACS from specimens taken at termination of the experiment and included analyses of animals that had been sacrificed at earlier
times throughout the duration of the study. n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1 were 44/15/15/14. (C). Same as panel A, but for the bone
marrow of 37-week-oldmice. (D). Same as panel B, but for absolute numbers of CD138+ cells in the bonemarrow of two femurs and for 37-week-old
mice only. n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1 were 25/15/11/4. (E). Evolution of anti-dsDNA IgG levels in groups of control and treated mice.
Mice that had to be sacrificed before week 37 are indicated with black circles. n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1 were 44/15/15/14. (F).
Log10 of fold change of anti-dsDNA levels between week 24 and week 37. Only NZB/NZW F1 mice with less than 100 arbitrary units of anti-dsDNA
antibody at week 24 were included in this analysis. n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1 were 28/10/12/8. (G). Renal histology scores for the
different treatment groups at sacrifice (week 37 or earlier). n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1 were 45/15/15/15. (H). Relationship between
anti-dsDNA titers at early time points (average of titers measured at weeks 24 and 28) and a proteinuria score taking into account timing of
apparition and severity of proteinuria. n for controls/TACI-Fc/BAFFR-Fc/Apry-1-1 were 43/15/15/14. Panels A-H are from an experiment that was
performed once. Panels A-D, F, and G show mean of each group ± SEM. Symbols represent individual mice. Statistical analysis was performed
with one-way ANOVA followed by Bonferroni comparing controls to each treatment. ns: non-significant; *p < 0.05; **p < 0.01, ***p < 0.001.
comparatively very low levels of endogenous APRIL. Indeed, in a
different experimental system, glycolipid-anchored mBAFFR, but
not hBAFFR, could specifically cross react with APRIL [42]. In
another study performed in NZB/NZW F1 mice, BAFFR-Fc was
tested at week 24 (100 μg ip, three times a week, until week 29),
long before proteinuria became visible (50% of untreated mice
had proteinuria at week 42). The species of BAFFR-Fc used was
not reported and TACI-Fc was not tested in this study, but there
was a positive impact of treatment on proteinuria and survival
(40% in untreated versus 100% in treated at week 52) [28].
In control groups of NZB/NZW F1 mice, we found that autoan-
tibody levels at the beginning of disease often correlated with
a proteinuria score at the end of the disease (Fig. 2H). This
score took into account timing of the first detection of protein-
uria and average proteinuria levels during the last 4 weeks of the
experiment. This correlation was broken in TACI-Fc-treated mice,
where even mice with high autoantibody levels did not develop
proteinuria. The observation that TACI-Fc treatment decreased
PCs in the bone marrow and slowed down autoantibody for-
mation cannot explain alone protection observed in mice with
high autoantibody levels and suggest involvement of other mech-
anisms. It has been shown in the NZM 2410 non-inflammatory
SLE model that immune complex deposition in kidney could
be uncoupled from renal pathology in adenovirus-mBAFFR-Fc
C© 2017 The Authors. European Journal of Immunology published by
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Figure 3. mTACI-Fc prevents renal immunopathology in
NZB/NZW F1 mice. Kidney sections from 37 week-old
NZB/NZW F1 mice treated as indicated and stained with
hematoxylin and eosin (H&E), or stained by immuno-
histochemistry for IgG1 or IgG2a. (A) mFc-treated (con-
trol) mouse. (B) mTACI-Fc-treated mouse. (C) mBAFFR-Fc
treated mice. (D) Apry-1-1-treated mouse. Original magni-
fications × 200 for H&E and × 100 for IHC. Scale bars: 50
μm. Data were used to determine histopathology scores of
Fig. 2G. Images are from a single experiment with 15 mice
per group (except controls: 45 mice) and are representative
of animals with median histopathology scores (see Fig. 2G)
without proteinuria (15/15 for mTACI-Fc) or with protein-
uria (28/45 for controls, 7/15 for mBAFFR-Fc, and 7/15 for
Apry-1-1).
treatedmice [29]. Indeed, BAFF inhibition prevented renal pathol-
ogy, reduced splenic B cells and induced a small spleen size, but
did not prevent immune complex deposition in kidneys. Small
spleens contain fewer numbers of activated CD4 T cells and
CD11b macrophages/dendritic cells, which may account for the
observed decreased activation of resident dendritic cells in kidney,
decreased activation of renal endothelial cells and preservation of
podocytes, which are part of the glomerular filtration barrier [29].
Thus, autoantibodies and immune complexes could collaborate
with other (inflammatory) mediators to damage kidney. TACI-Fc
may affect both processes to exert its protective effect.
Here we observe that, at least in the specific conditions of our
experiment, mTACI-Fc was active when mBAFFR-Fc was not or
little. This could be due to APRIL inhibition. For example, APRIL-
deficient mice displayed reduced IL-17 secretion and had reduced
collagen-induced arthritis manifestations [43]. But it could also
be due to a distinct activity of TACI-Fc. The question of whether
APRIL inhibition can explain the protective effect of TACI-Fc will
be clarified when reagents that specifically block mouse APRIL but
that are not neutralized in autoimmune mice become available.
With regard to BAFF and/or APRIL requirement of long-lived
bone marrow PCs in immunized, non-autoimmune mice, a previ-
ous, elegant study has compared the outcome of treatments with
TACI-Fc or BAFFR-Fc in wild type and APRIL-ko mice. TACI-Fc
always decreased long-lived PCs, but BAFFR-Fc did so only in
APRIL-ko mice [40], leading to the conclusion that long-lived PCs
use either BAFF and/or APRIL as survival factors in vivo. We used
a pharmacological inhibitor of APRIL instead of APRIL-ko mice
and got identical conclusions for newly generated bone marrow
PCs, but not for long-lived ones that were sensitive to TACI-Fc,
but not to BAFFR-Fc/anti-APRIL administered together. It is an
intriguing possibility that these results may reflect a role of het-
eromers of BAFF and APRIL [4–6] in the biology of PCs. Indeed,
an anti-APRIL antibody may not inhibit heteromers of BAFF and
APRIL, while no heteromer can form in APRIL-ko mice. The devel-
opment of reagents that can specifically block mouse APRIL/BAFF
C© 2017 The Authors. European Journal of Immunology published by
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Figure 4. mandhTACI-Fc, notmBAFFR-Fc, efficiently deplete bonemarrow PC in immunized C56BL/6mice, while efficacy of Apry-1-1 alone orwith
mBAFFR-Fc varies as PCs mature. C57BL/6 mice were immunized at 8 weeks of age with NP-conjugated keyhole limpet hemocyanin precipitated
in Alum. 2, 5, or 12 weeks later, mice were treated for two additional weeks, three times a week, with either mTACI-Fc, hTACI-Fc, mBAFFR-Fc,
anti-mAPRIL Apry-1-1 or control reagents. Data shown combine results of two independent experiments each with n = 5 animals per group (with
the exception of hTACI-Fc and intravenous immunoglobulin (IVIG) that were performed once). (A). Quantification of mouse BAFF-blocking activity
in sera of treated mice at the end of the experiment, using a BCMA:Fas reporter cell line. (B). Same as panel C, but for the quantification of mouse
APRIL-blocking activity. (C). Relative absolute numbers of splenic B cells (CD19+/B220+), compared to the mean of a control group (mIg + mFc).
(D). Relative absolute numbers of bone marrow NP-specific IgG antibody-secreting cells (ASC) measured by ELISPOT compared to the mean of a
control group. Mice were treated with the indicated inhibitors from weeks 2 to 4 (weeks 2–4), 5 to 7 (weeks 5–7), or 12 to 14 (weeks 12–14) post
immunization and analyzed at the end of this 2-week treatment. All graphs show mean ± SEM. Symbols represent individual mice. Analyses
in panels A and B were performed twice with similar results. Statistical analysis was performed with one way ANOVA followed by Bonferroni
comparing controls to each treatment (A–D). ns: nonsignificant; *p < 0.05; **p < 0.01; ***p < 0.001; (ns): nonsignificant in one way ANOVA, but ***
when compared to mIg + mFc with unpaired t-test. For panels A and B, only hTACI-Fc is significantly different from all other groups by one way
ANOVA (p < 0.001). The line of statistical results that is shown in panel A compares controls to inhibitors of similar potency (i.e., excluding the
group of hTACI-Fc) by one-way ANOVA. For panel B, inhibitors of medium activity (Apry-1-1, upper line of statistical results) and of weak activity
(mTACI-Fc, lower line of statistical results) are independently compared to controls by one-way ANOVA.
heteromers, would help assessing the putative role of heteromers
in PC biology.
Materials and methods
Mice and spontaneous SLE model
Protocols had been legally approved and experiments were con-
ducted in accredited facilities in accordance with Merck KGaA
Institutional Animal Care and Use Committee (IACUC) guidelines
and compliant with regulations set by the German animal protec-
tion law, enforced by the Regierungspra¨sidium, Darmstadt, Hes-
sen, Germany (authorizations DA4/205 and DA4/222). Mice were
housed in specific pathogen-free, barrier facilities at all times.
Female F1 hybrid mice NZBWF1/J (the progeny of female
NZB/BlNJ and male NZW/LacJ) were purchased from The Jack-
son Laboratory. Blood and urine samples were collected for lon-
gitudinal monitoring of autoantibodies and urine protein content,
starting at 16 weeks of age. C57BL/6 mice were purchased from
Charles River Laboratories. MRLlpr/lpr mice were purchased from
Harlan Laboratories.
Antibodies and recombinant proteins
Fc-mBAFF, and Fc-mAPRIL were produced essentially as described
(reviewed in Schneider, et al 2014 [44]). A single-chain human
neutralizing anti-mouse APRIL antibody fused to mouse IgG2b
(Apry-1-1) was obtained from Adipogen (Epalinges, Switzerland).
hTACI (aa 31–110) - hIgG1 Fc (aa 245–470, L258E, A353S,
P354S) (atacicept, [41]) was obtained from Merck KGaA. mTACI
(aa 2–82) - mIgG2 Fc (L235E, E318A, K320A, K322A), mBAFFR
(aa 2–76) - mIgG2c Fc (L235E, E318A, K320A, K322A), mouse
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IgG2c Fc (L235E, E318A, K320A, K322A) and mouse IgG2b (clone
MCP-11) were originally from Zymogenetics and provided by
Merck KGaA. Mutations in the Fc domains disrupt binding to Fc
receptors and complement, as described [40].
Immunizations and treatments
NZB/NZW F1 mice were randomly assigned to experimental
groups and received test articles starting at week 25, when the
majority of animals had developed significantly increased anti-
dsDNA autoantibody titers. mTACI-Fc, mBAFFR-Fc, anti-mouse
APRIL Apry-1-1, mouse Fc fragment (mFc), or mouse isotype con-
trol (mIg) were administered i.p. at 5 mg/kg, three times per week
on a Monday/Wednesday/Friday schedule for 12 weeks. Serum
and urine samples were collected for anti-dsDNA antibodies (by
ELISA) and urinary protein to creatinine ratio (UPCR) (measured
by ADVIA 1800) determination, respectively, on the days indi-
cated. Proteinuria was defined as when UPCR was  3. A pro-
teinuria score was defined as the average UPCR at weeks 34, 35,
36, and 37 divided by the number of proteinuria-free weeks since
week 22. For mice sacrificed before week 34 because of protein-
uria, the value of the last UPCR measure was used to calculate the
proteinuria score.
For hapten/carrier immunizations, 6 to 8 weeks-old mice were
immunized i.p. with 100 μg of NP-conjugated keyhole limpet
hemocyanin adsorbed to alum (Imject
R©
, Pierce) in a volume of
200 μL. After immunization, mice were treated three times a week
for 2 weeks with test articles or controls at 5 mg/kg, starting at
week 2, 5, or 12 post-immunization. Mice were then sacrificed and
tissues harvested.
Histology
Sections of formalin-fixed kidneys harvested from NZB/NZW F1
mice post mortemwere stained with hematoxylin and eosin (H&E)
and were blindly assessed by light microscopy for inflammation,
glomerular damage and sclerosis. Glomerular activity (hyper-
cellularity, necrotizing lesions, karyorrhexis, cellular crescents,
hyaline deposits), tubulointerstitial activity (interstitial cellular
infiltration, tubular cell necrosis), chronic glomerular pathology
(glomerulosclerosis, fibrous crescents), and chronic tubulointersti-
tial pathology (tubular atrophy, interstitial fibrosis) were assessed
as follows and subjectively scored on a 0–4 scale, for a maximum
composite score of 12: Inflammation: Grade 1, mild focal intersti-
tial inflammation; grade 2, multifocal areas of mild interstitial
inflammation; grade 3, moderate multifocal interstitial inflam-
mation; grade 4, significant multifocal interstitial inflammation.
Glomerular damage: Grade 1, initial glomerular lesions; initial
lesions are characterized by increased cellular components in sin-
gle or few glomeruli, cellular proliferation and basement mem-
brane thickening; grade 2, multifocal areas of glomerular lesions;
grade 3, multifocal areas of glomerular lesions with significant
damage characterized by proliferation of epithelial cells of cap-
sule of Bowman with compression of glomerular capillaries; grade
4, pronounced multifocal to generalized glomerular damage (i.e.
grade 3 plus obliteration of Bowman space, glomerular compres-
sion and hyalinosis). Glomerular sclerosis: Grade 1, focal mild
glomerular sclerosis; grade 2, multifocal mild glomerular sclero-
sis; grade 3, severe focal glomerular sclerosis; grade 4, severe
multifocal glomerular sclerosis.
Determination of anti-dsDNA titers
ELISA plates were coated with 10 μg of calf thymic DNA
(Sigma) in 0.1 M Na carbonate buffer pH 9.6, blocked, exposed
to serial dilutions of sera, and revealed with horseradish
peroxidase-coupled goat anti-mouse IgG antibodies and 3,3′,5,5′-
tetramethylbenzidine (Sigma-Aldrich). Anti-dsDNA antibody lev-
els were calculated as arbitrary units compared to a pooled stan-
dard serum from 22-week-old MRLlpr/lpr mice.
Immunofluorescence
Tissues were snap-frozen and 5 μm sections were fixed with
methanol prior to staining for 1 h at room temperature with FITC-
conjugated anti-mouse IgG1 or IgG2a (Southern Biotech). Slides
were analyzed with an Axio Imager 2 (Zeiss) used at 100× mag-
nification. Images were captured using a CCD camera (AXIOCam
MRm Zeiss).
Detection of antibody-secreting cells by ELISPOT
ELISPOT plates (Millipore) were coated with 10 μg/mL of goat
anti-mouse IgG (Calbiochem) or 10 μg/mL of NP-BSA (Biosearch
Technologies) in 0.1 M carbonate buffer pH 9.6 and washed with
PBS. Serial dilutions of bone marrow cell or splenocytes were
incubated for 5 h, followed by washing with PBS and incubation
with secondary horse radish peroxydase-conjugated anti-mouse
IgG (Sigma). After washing, plates were developed with AEC
staining Kit (Sigma) until spots became visible with bare eyes,
then washed with water and dried. Spots were counted with an
ELISPOT reader (AID)
Flow cytometry
Spleens were harvested, and splenocytes were prepared accord-
ing to conventional procedures, including a red blood cell lysis
step in 156 mM NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH
7.3 (ACK lysis buffer) for 10 min at room temperature. Spleno-
cytes were incubated in Fc-block (anti CD16/32) then stained with
CD19-APC-Cy7 (Biolegend), B220 pacific orange (Invitrogen) and
CD138 APC (BD Bioscience) antibodies. Cells were analyzed using
a FACS Canto flow cytometer (BectonDickinson) and FlowJo soft-
ware (TreeStar, Ashland, OR).
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In vitro cytotoxicity assays
A Fas-deficient reporter cell line Jurkat JOM2 BCMA:Fas-2309
cl56 was generated as previously described [44]. These cells
are more sensitive (three- to 10-fold) than the previously
reported Jurkat BCMA:Fas-2309 cl13 cells [45]. Cells were
exposed overnight to titrated amounts of Fc-mAPRIL or Fc-
mBAFF, in the presence of fixed amounts of inhibitor-containing
sera in a total volume of 100 μL of RPMI medium supple-
mented with 10% fetal calf serum and antibiotics, after which
time cell viability was measured by the phenazine methosul-
fate / 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (PMS/MTS) assay essentially as
described [44]. Fc-mAPRIL was used at a first final concentration
of 40 ng/mL, with 12 three-fold dilutions (except when measur-
ing hTACI-Fc activity: first final concentration of 500 ng/mL, with
four-fold dilutions). Fc-mBAFF was used at a first final concentra-
tion of 100 ng/mL, with three-fold dilutions. Sera of treated mice
were tested at a final dilution of 1/300. EC50 were determined
for each titration curve using the “log(agonist) versus normalized
response – Variable slope” function of the Prism software. For the
measure of anti-Apry-1-1 neutralizing antibody response, Jurkat
BCMA:Fas-2309 cl13 were exposed to a fixed, lethal concentration
of Fc-mAPRIL (1 ng/mL) in the presence of titrated amounts of
fresh Apry-1-1 (to inhibit Fc-mAPRIL) and of a fixed dilution of
sera from control- or Apry-1-1-treated NZB/NZW F1 mice.
Statistics
Statistical analyses were performed with the Prism software, as
described in the figure legends.
Acknowledgements: We thank Laure Willen (University of
Lausanne), Nicole Wienandt, Annika Brunner, Bjo¨rn Schneider,
Alexandra Hohenstein, and Felix Jaeger (all Merck KGaA) for
expert technical assistance. This work was supported by Merck
KGaA. P.S. received support from the Swiss National Science Foun-
dation and from Merck KGaA.
Conflict of interest: P.H. and H.H. are employees of Merck KGaA,
Germany. P.S. is supported by a research grant from EMD Serono,
a subsidiary of Merck, KGaA. M.V. and J.N. declare no commercial
or financial conflict of interest.
References
1 Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., Feng, P.,
Soppet, D. et al., BLyS: member of the tumor necrosis factor family and
B lymphocyte stimulator. Science 1999. 285: 260–263.
2 Schneider, P.,MacKay, F., Steiner, V., Hofmann, K., Bodmer, J. L., Holler,
N., Ambrose, C. et al., BAFF, a novel ligand of the tumor necrosis factor
family, stimulates B cell growth. J. Exp. Med. 1999. 189: 1747–1756.
3 Hahne, M., Kataoka, T., Schroter, M., Hofmann, K., IrmLer, M., Bodmer,
J. L., Schneider, P. et al., APRIL, a new ligand of the tumor necrosis factor
family, stimulates tumor growth. J. Exp.Med. 1998. 188: 1185–1190.
4 Dillon, S. R., Harder, B., Lewis, K. B., Moore, M. D., Liu, H., Bukowski,
T. R., Hamacher, N. B. et al., B-lymphocyte stimulator/a proliferation-
inducing ligand heterotrimers are elevated in the sera of patients
with autoimmune disease and are neutralized by atacicept and B-
cell maturation antigen-immunoglobulin. Arthritis Res. Ther. 2010. 12:
R48.
5 Roschke, V., Sosnovtseva, S., Ward, C. D., Hong, J. S., Smith, R., Albert,
V., Stohl, W. et al., BLyS and APRIL form biologically active heterotrimers
that are expressed in patients with systemic immune-based rheumatic
diseases. J. Immunol. 2002. 169: 4314–4321.
6 Schuepbach-Mallepell, S., Das, D., Willen, L., Vigolo, M., Tardivel, A.,
Lebon, L., Kowalczyk-Quintas, C. et al., Stoichiometry of heteromeric
BAFF and APRIL cytokines dictates their receptor-binding and signaling
propoerties. J. Biol. Chem. 2015. 290: 16330–16342.
7 Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden,
K., Xu, W. et al., TACI and BCMA are receptors for a TNF homologue
implicated in B-cell autoimmune disease. Nature 2000. 404: 995–999.
8 Laabi, Y., Gras, M. P., Brouet, J. C., Berger, R., Larsen, C. J. and Tsapis, A.,
The BCMA gene, preferentially expressed during B lymphoidmaturation,
is bidirectionally transcribed. Nucleic Acids Res. 1994. 22: 1147–1154.
9 von Bulow, G. U. and Bram, R. J., NF-AT activation induced by a CAML-
interacting member of the tumor necrosis factor receptor superfamily.
Science 1997. 278: 138–141.
10 Thompson, J. S., Bixler, S. A., Qian, F., Vora, K., Scott, M. L., Cachero,
T. G., Hession, C. et al., BAFF-R, a newly identified TNF receptor that
specifically interacts with BAFF. Science 2001. 293: 2108–2111.
11 Hendriks, J., Planelles, L., de Jong-Odding, J., Hardenberg, G., Pals, S. T.,
Hahne, M., Spaargaren, M. et al., Heparan sulfate proteoglycan binding
promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 2005.
12: 637–648.
12 Ingold, K., Zumsteg, A., Tardivel, A.,Huard, B., Steiner, Q. G., Cachero, T.
G., Qiang, F. et al., Identification of proteoglycans as the APRIL-specific
binding partners. J. Exp. Med. 2005. 201: 1375–1383.
13 Gross, J. A., Dillon, S. R., Mudri, S., Johnston, J., Littau, A., Roque, R.,
Rixon, M. et al., TACI-Ig neutralizes molecules critical for B cell devel-
opment and autoimmune disease. impaired B cell maturation in mice
lacking BLyS. Immunity 2001. 15: 289–302.
14 Schiemann, B., Gommerman, J. L., Vora, K., Cachero, T. G., Shulga-
Morskaya, S., Dobles, M., Frew, E. et al., An essential role for BAFF in
the normal development of B cells through a BCMA-independent path-
way. Science 2001. 293: 2111–2114.
15 Castigli, E., Scott, S., Dedeoglu, F., Bryce, P., Jabara, H., Bhan, A. K.,
Mizoguchi, E. et al., Impaired IgA class switching in APRIL-deficientmice.
Proc. Natl. Acad. Sci. USA 2004. 101: 3903–3908.
16 Yan, M., Brady, J. R., Chan, B., Lee, W. P., Hsu, B., Harless, S., Cancro,
M. et al., Identification of a novel receptor for B lymphocyte stimulator
that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol.
2001. 11: 1547–1552.
17 von Bulow, G., van Deursen, J. M. and Bram, R. J. Regulation of the t-
independent humoral response by taci. Immunity 2001. 14: 573–582.
18 Yan, M., Wang, H., Chan, B., Roose-Girma, M., Erickson, S., Baker, T.,
Tumas, D. et al., Activation and accumulation of B cells in TACI-deficient
mice. Nat. Immunol. 2001. 2: 638–643.
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
Eur. J. Immunol. 2017. 47: 1075–1085 Immunomodulation and immune therapies 1085
19 O’Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K.,
Ahonen, C., Lin, L. et al., BCMA is essential for the survival of long-lived
bone marrow plasma cells. J. Exp. Med. 2004. 199: 91–97.
20 Jourdan, M., Cren, M., Robert, N., Bollore, K., Fest, T., Duperray, C., Guil-
loton, F. et al., IL-6 supports the generation of human long-lived plasma
cells in combination with either APRIL or stromal cell-soluble factors.
Leukemia 2014. 28: 1647–1656.
21 Cheema, G. S., Roschke, V., Hilbert, D. M. and Stohl, W., Elevated serum
B lymphocyte stimulator levels in patients with systemic immune-based
rheumatic diseases. Arthritis Rheum. 2001. 44: 1313–1319.
22 Eilertsen, G. O. and Nossent, J. C., APRIL levels strongly correlate with
IL-17 in systemic lupus erythematosus. Lupus 2014. 23: 1383–1391.
23 Groom, J., Kalled, S. L., Cutler, A. H., Olson, C., Woodcock, S. A., Schnei-
der, P., Tschopp, J. et al., Association of BAFF/BLyS overexpression and
altered B cell differentiation with Sjogren’s syndrome. J. Clin. Invest. 2002.
109: 59–68.
24 Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M.,
Schneider, P., Tschopp, J. et al., Mice transgenic for BAFF develop lym-
phocytic disorders along with autoimmune manifestations. J. Exp. Med.
1999. 190: 1697–1710.
25 Thien, M., Phan, T. G., Gardam, S., Amesbury, M., Basten, A.,Mackay, F.
and Brink, R., Excess BAFF rescues self-reactive B cells from peripheral
deletion and allows them to enter forbidden follicular andmarginal zone
niches. Immunity 2004. 20: 785–798.
26 Lesley, R., Xu, Y., Kalled, S. L., Hess, D. M., Schwab, S. R., Shu, H. B. and
Cyster, J. G., Reduced competitiveness of autoantigen-engaged B cells
due to increased dependence on BAFF. Immunity 2004. 20: 441–453.
27 Ding, H.,Wang, L.,Wu, X.,Yan, J.,He, Y.,Ni, B.,Gao,W. et al., Blockade of
B-cell-activating factor suppresses lupus-like syndrome in autoimmune
BXSB mice. J. Cell Mol. Med. 2010. 14: 1717–1725.
28 Kayagaki, N., Yan, M., Seshasayee, D.,Wang, H., Lee, W., French, D. M.,
Grewal, I. S. et al., BAFF/BLyS receptor 3 binds the B cell survival factor
BAFF ligand through a discrete surface loop and promotes processing of
NF-kappaB2. Immunity 2002. 17: 515–524.
29 Ramanujam, M., Bethunaickan, R., Huang, W., Tao, H., Madaio, M. P.
and Davidson, A., Selective blockade of BAFF for the prevention and
treatment of systemic lupus erythematosus nephritis in NZM2410 mice.
Arthritis Rheum. 2010. 62: 1457–1468.
30 Ramanujam, M.,Wang, X.,Huang,W., Liu, Z., Schiffer, L., Tao, H., Frank,
D. et al., Similarities and differences between selective and nonselective
BAFF blockade in murine SLE. J. Clin. Invest. 2006. 116: 724–734.
31 Ramanujam, M., Wang, X., Huang, W., Schiffer, L., Grimaldi, C., Akker-
man, A., Diamond, B. et al., Mechanism of action of transmembrane
activator and calciummodulator ligand interactor-Ig in murine systemic
lupus erythematosus. J. Immunol. 2004. 173: 3524–3534.
32 Huard, B.,Tran, N. L., Benkhoucha, M.,Manzin-Lorenzi, C. and Santiago-
Raber, M. L., Selective APRIL blockade delays systemic lupus erythemato-
sus in mouse. PLoS One 2012. 7: e31837.
33 Coquery, C. M.,Wade, N. S., Loo, W. M., Kinchen, J. M., Cox, K. M., Jiang,
C., Tung, K. S. et al., Neutrophils contribute to excess serum BAFF levels
and promote CD4+ T cell and B cell responses in lupus-prone mice. PLoS
One 2014. 9: e102284.
34 Jacob, C. O., Guo, S., Jacob, N., Pawar, R. D., Putterman, C., Quinn, W. J.,
3rd., Cancro, M. P. et al., Dispensability of APRIL to the development of
systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012.
64: 1610–1619.
35 Jacob, C. O., Pricop, L., Putterman, C., Koss, M. N., Liu, Y., Kollaros, M.,
Bixler, S. A. et al., Paucity of clinical disease despite serological autoim-
munity and kidney pathology in lupus-prone New Zealand mixed 2328
mice deficient in BAFF. J. Immunol. 2006. 177: 2671–2680.
36 Jacob, C. O., Yu, N., Guo, S., Jacob, N., Quinn, W. J., 3rd., Sindhava, V.,
Cancro, M. P. et al., Development of systemic lupus erythematosus in
NZM 2328 mice in the absence of any single BAFF receptor. Arthritis
Rheum. 2013. 65: 1043–1054.
37 Jacob, C. O., Yu, N., Sindhava, V., Cancro, M. P., Pawar, R. D., Putterman,
C. and Stohl, W., Differential development of systemic lupus erythe-
matosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors.
Arthritis Rheumatol. 2015. 67: 2523–2535.
38 Bossen, C. and Schneider, P., BAFF, APRIL and their receptors: structure,
function and signaling. Semin. Immunol. 2006. 18: 263–275.
39 Kowalczyk-Quintas, C., Schuepbach-Mallepell, S., Vigolo, M., Willen, L.,
Tardivel, A., Smulski, C. R., Zheng, T. S. et al., Antibodies that block or
activatemouse B cell activating factor of the TumorNecrosis Factor (TNF)
Family (BAFF), respectively, induce B cell depletion or B cell hyperplasia.
J. Biol. Chem. 2016. 291: 19826–19834.
40 Benson, M. J., Dillon, S. R., Castigli, E., Geha, R. S., Xu, S., Lam, K. P.
and Noelle, R. J., Cutting edge: the dependence of plasma cells and inde-
pendence of memory B cells on BAFF and APRIL. J. Immunol. 2008. 180:
3655–3659.
41 Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P. and Wofsy,
D., Efficacy and safety of atacicept for prevention of flares in patients
with moderate-to-severe systemic lupus erythematosus (SLE): 52-week
data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 2015. 74: 2006–
2015.
42 Bossen, C., Ingold, K., Tardivel, A., Bodmer, J. L., Gaide, O., Hertig, S.,
Ambrose, C. et al., Interactions of tumor necrosis factor (TNF) and TNF
receptor family members in the mouse and human. J. Biol. Chem. 2006.
281: 13964–13971.
43 Xiao, Y., Motomura, S. and Podack, E. R., APRIL (TNFSF13) regulates
collagen-induced arthritis, IL-17 production and Th2 response. Eur. J.
Immunol. 2008. 38: 3450–3458.
44 Schneider, P.,Willen, L. and Smulski, C. R., Tools and techniques to study
ligand-receptor interactions and receptor activation by TNF superfamily
members. Methods Enzymol. 2014. 545: 103–125.
45 Bossen, C., Cachero, T. G., Tardivel, A., Ingold, K.,Willen, L., Dobles, M.,
Scott, M. L. et al., TACI, unlike BAFF-R, is solely activated by oligomeric
BAFF and APRIL to support survival of activated B cells and plasmablasts.
Blood 2008. 111: 1004–1012.
Abbreviations: APRIL: A proliferation-inducing ligand · BAFF: B cell acti-
vating factor of the TNF family · BAFFR: BAFF receptor · BCMA: B cell
maturation antigen · Fc: fragment crystallizable of an antibody · NP:
4-hydroxy-3-nitrophenylacetyl hapten · PC: plasma cell · TACI: trans-
membrane activator and CAML [calcium-modulator and cyclophilin lig-
and] interactor · UPCR: urinary protein to creatinine ratio
Full correspondence: Henry Hess, Immunology TIP, Merck KGaA,






Accepted article online: 6/4/2017
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu







A mouse model of systemic lupus erythematosus responds better to soluble 
TACI than to soluble BAFFR, correlating with depletion of plasma cells.      
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Abbreviations: Flag: octapeptide tag with sequence DYKDDDDK. 293T cells: human 





Supporting Figure 1. Characterization of mAPRIL-neutralizing agents. 
TACI-Fc and the recombinant anti-mouse APRIL Apry-1-1 were compared in a panel of tests for 
their ability to bind and inhibit BAFF and/or APRIL in vitro 
A. Coomassie blue staining of 10 µg/lane of TACI-Fc and Apry-1-1.  
B. Apry-1-1 specifically recognizes mAPRIL. Flag-mBAFF, Flag-ACRP-mAPRIL or Flag-
ACRP-hAPRIL were coated in an ELISA plate and revealed with either hTACI-Fc, an anti-Flag 





antibody or Apry-1-1 reagents (or PBS as a control) as indicated, followed by appropriate horse 
radish peroxydase-coupled anti-human or anti-mouse antibodies for hTACI-Fc and Apry-1-1, 
respectively. 
C. Apry-1-1 specifically recognizes native mAPRIL. 293T cells were co-transfected with an 
enhanced green fluorescent protein (EGFP) tracer and with non-cleavable forms of mouse 
APRIL or BAFF. EGFP expression on the X-axis correlates with mAPRIL or mBAFF 
expression. Cells were stained by FACS with TACI-Fc or Apry-1-1, followed by appropriate 
phycoerythrin-coupled secondary reagents. Scattergrams show four orders of magnitude 
fluorescence on a logarithmic scale on both axes. Binding of hTACI-Fc or Apry-1-1 is revealed 
by an increased fluorescence on the Y axis (antibody binding). 
D. Apry-1-1 prevents the binding of mAPRIL to BCMA and TACI. 293T cells transfected with 
glycosyl-phosphatidylinositiol (GPI)-anchored BCMA or TACI were stained with titrated 
amounts of Flag-ACRP-mAPRIL either alone (none) or in the presence of the indicated fixed 
amount of TACI-Fc or Apry-1-1. The binding of Flag-ACRP-mAPRIL to BCMA or TACI was 
monitored using appropriate phycoerythrin-coupled secondary reagents and expressed as mean 
fluorescence intensity (MFI). 
E. Apry-1-1 specifically protects BCMA and TACI reporter cells from mAPRIL-mediated death. 
Reporter cells expressing the chimeric receptors BCMA:Fas or TACI:Fas activate a surrogate 
Fas apoptotic pathway in response to APRIL. Reporter cells had been exposed to a lethal dose of 
Flag-ACRP-mAPRIL, in the presence or absence of increasing concentrations of TACI-Fc or 
Apry-1-1. The presence of viable cells, monitored with a cell viability assay, indicates that 
mAPRIL activity has been neutralized.  
F. BCMA:Fas-2309 cl13 reporter cells were exposed to titrated amounts of Fc-mAPRIL in the 
presence of fixed concentrations of Apry-1-1, as indicated. Cell viability was monitored to 
determine EC50 of Fc-mAPRIL activity in the presence of various concentrations of Apry-1-1. 
These data were used to draw the curve of Apry-1-1 in panel H. 
G, H. EC50 of Fc-mBAFF (panel G) or Fc-mAPRIL (panel H) on BCMA:Fas-2309 cl13 reporter 
cells plotted as a function of inhibitor concentration. Linear regression curves were determined 
for EC50 values above the lower limit of quantification. 
 
 
In vitro characterization of a function-
blocking anti-mouse APRIL antibody – As 
BCMA participates to survival and longevity 
of PCs in the bone marrow [1], and displays a 
higher affinity for APRIL than for BAFF [2], 
APRIL is likely to transmit survival signal to 
PCs. We thus characterized an anti-APRIL 
antibody suitable for pharmacological 
inhibition of mouse APRIL. This reagent, 
Apry-1-1, is a single chain monoclonal 
antibody dimerized by fusion to the Fc portion 
of mouse IgG2b. The analysis of Apry-1-1 
protein by Coomassie blue, or of hTACI-Fc as 
a control, revealed single bands of expected 
sizes with the presence of minor unidentified 
degradation products or contaminants in the 
case of Apry-1-1 (Suppl. Fig. 1A). Both 
reagents recognized Flag-mAPRIL coated in 
an ELISA plate, while, as expected, only 
hTACI-Fc additionally recognized Flag-
mBAFF and Flag-hAPRIL (Suppl. Fig. 1B). 
Similar results were obtained when 
uncleavable forms of mAPRIL and mBAFF 
were expressed at the surface of transfected 
293T cells, further indicating that Apry-1-1 
and hTACI-Fc also recognize native 
conformations of their targets (Suppl. Fig. 1C). 
These results indicate that hTACI-Fc binds to 
BAFF and APRIL, while Apry-1-1 is specific 
for mouse APRIL. Tests were then performed 





to assess the inhibitory potential of Apry-1-1. 
293T cells were transfected with glycolipid-
anchored forms of BCMA or TACI to ensure 
efficient surface expression of the receptors 
[3], and stained with increasing concentrations 
of Flag-ACRP-mAPRIL. When stainings were 
performed in the presence of Apry-1-1 or 
TACI-Fc, the binding of mouse APRIL was 
decreased or even abolished at sufficient 
inhibitor to ligand ratio (20 and 200 mass 
excess of hTACI-Fc, respectively Apry-1-1, 
over mAPRIL), indicating that the inhibitors 
can interfere with the binding of mouse 
APRIL to its receptors (Suppl. Fig. 1D).  
The functionality of anti-APRIL 
reagents was assessed in reporter cell lines 
expressing the extracellular domains of 
BCMA [4] or of TACI cysteine-rich domains 
1 and 2 [5] fused to the transmembrane and 
intracellular domains of the death receptor Fas, 
so that engagement of these chimeric receptors 
with APRIL results in transmission of 
apoptotic signals and cell death. These cells 
were totally killed by 30 ng/ml of Flag-ACRP-
mAPRIL, an active recombinant form of 
APRIL, but were specifically rescued in a 
dose-dependent manner by both hTACI-Fc or 
Apry-1-1 with EC50 of around 0.3 µg/ml 
(Suppl. Fig. 1E).  
In conclusion, these experiments 
suggest that the single-chain anti-mouse 
APRIL antibody is capable of binding and 
inhibiting mouse APRIL in a variety of tests in 
vitro and compares favorably with TACI-Fc in 
terms of mouse APRIL inhibition.  
 
Supporting Figure 2. Gating strategies for FACS analyses. 
Examples shown are from NZB/NZW F1 mice. Identical strategies were applied to C57BL/6 mice.  
A. Quantification of CD138+ cells in the bone marrow.  










Antibodies and recombinant proteins – 
Flag-mBAFF, Flag-ACRP-mAPRIL and Flag-
ACRP-hAPRIL were produced essentially as 
described (reviewed in [6]). Mouse IgG1 anti-
Flag M2 (± biotinylation) was from Sigma. 
 
ELISA for the detection of Flag-APRIL –  
Nunc Maxisorp 96-wells immunoplates were 
coated with Flag-mBAFF, Flag-ACRP-
mAPRIL or Flag-ACRP-hAPRIL at 1 µg/ml in 
PBS. After saturation of wells, proteins were 
revealed with hTACI-Fc, Apry-1-1 or anti-
Flag M2 at 2 µg/ml, followed by appropriate 
horse radish peroxydase-coupled secondary 
reagents and o-phenylenediamine (OPD) 
substrate (Sigma). Reactions were stopped 
with HCl, and absorbance monitored at 490 
nm. 
 
Flow cytometry – 293T cells were co-
transfected by the calcium phosphate method 
with an enhanced green fluorescent protein 
(EGFP) tracer expression plasmid and 
plasmids coding for non-cleavable forms of 
mouse BAFF and mouse APRIL, stained with 
hTACI-Fc or Apry-1-1 at 5 µg/ml, followed by 
appropriate phycoerythrin-coupled secondary 
reagents essentially as described [7]. 293T 
cells transfected with glycolipid-anchored 
forms of human BCMA or mouse TACI were 
stained in 50 µl with 100, 10, 1, 0.1 or 0 
ng/staining of Flag-ACRP-mAPRIL in the 
presence or absence of 200 ng/staining of 
TACI-Fc or Apry-1-1. Bound Flag-ACRP-
APRIL revealed with biotinylated M2 and 
phycoerythrin-coupled streptavidin was 
quantified as mean fluorescence intensity in 
cells expressing medium levels (MFI 100 to 
1000) of EGFP essentially as described [6].  
 
In vitro cytotoxicity assays – The reporter cell 
line Jurkat BCMA:Fas-2309 cl13 was as 
previously described [4]. Reporter cells Jurkat 
JOM2 TACI:Fas-2454 cl111 were generated 
according to a published protocol [6]. 
Receptor:Fas reporter cells were exposed to 30 
ng/ml of Flag-ACRP-mAPRIL in the presence 
or absence of graded amounts of hTACI-Fc or 
Apry-1-1. After overnight incubation, cell 
viability was monitored with the PMS/MTS 
cell viability assay as described [6]. In other 
experiments, Jurkat BCMA:Fas-2309 cl13  
were exposed to Fc-mAPRIL (500 ng/ml and 
three-fold dilutions for strong inhibitors, or 20 
ng/nl and two-fold dilutions for weak 
inhibitors) or Fc-mBAFF (400 ng/ml and two-
fold dilutions) in the presence of 500, 125, 32, 
8, 2, 0.5, 0.125 or 0 ng/ml of hTACI-Fc, Apry-
1-1, mTACI-Fc or mBAFFR-Fc. EC50 were 
determined for each titration curve using the 
“log(agonist) vs. normalized response -- 
Variable slope” function of Prism. 
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Suporting Table 1. Plasmids used in this study.  
 
Plasmid Designation Protein encoded Vector 
ps015 Empty vector None PCR3 
ps515 EGFP Enhanced green fluorescent protein PCR3 
ps657 Flag-mBAFF HA signal-Flag-GPGQVQLQVD-mBAFF (aa 127-309) PCR3 
ps813 hBAFF N-
mAPRIL 
hBAFF (aa 1-132)-LQ-mAPRIL (aa96-240) PCR3 
px1003 hBAFF N-
mBAFF 
hBAFF (aa 1-132)-LQVD-mBAFF (aa128-309) PCR3 
ps1153 Fc-mAPRIL HA signal-LD-hIgG1 (aa 245-470)-RSPQPQPKPQPKPEPEGSLQ-mAPRIL (aa 
96-240) 
PCR3 
ps1159 mTACI-GPI Ig signal-LE-mTACI (aa 2-78)-AAAVD-hTRAILR3 (aa 157-269) PCR3 





HA signal-Flag-GPGQVQLH-mACRP30 (aa 18-111)-LQ-mAPRIL (aa 106-
240) 
PCR3 
ps1377 pMSCV-puro Modified pMSCV-puro (Clonetech) with HindIII-BglII-EcoRI-NotI-XhoI-HpaI-
ApaI cloning sites 
ps1377 
ps1467 hBCMA-GPI Ig signal-VQCEVKLVPRGS-hBCMA (aa 2-54)-VD-hTRAILR3 (aa 157-269) PCR3 
ps1623 Flag-ACRP-
hAPRIL 
HA signal-Flag-GPGQVQLH-mACRP30 (aa 18-111)-LQ-hAPRIL (aa 98-233) PCR3 
ps2309 hBCMA:Fas Ig signal-VQCEVKLVPRGS-hBCMA (aa 2-54)-VD-hFas (aa 169-335) ps1377 
ps2455 hTACI:Fas HA signal-L-hTACI (aa 67-118)-VD-hFas (aa 169-335) ps1377 
       Flag = DYKDDDDK    HA signal=MAIIYLILLFTAVRG        Ig signal=MNFGFSLIFLVLVLKG  
 
 
 
